Clinical Trial

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims…

6 months ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA…

6 months ago

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric brain cancer…

6 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech,…

6 months ago

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting…

6 months ago

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule…

6 months ago

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation…

6 months ago

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…

6 months ago

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million…

6 months ago

Celly Nutrition Forges Strategic Partnership with BevSource to Accelerate unbuzzd(TM) Distribution

Toronto, Ontario--(Newsfile Corp. - April 22, 2024) - In a strategic move in preparation of the launch in the United…

6 months ago